美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

卡利都斯軟件

36.00

0.0000

成交量：- -

成交額：- -

市值：23.93億

市盈率：-115.91

高：36.00

開：36.00

低：36.00

收：36.00

52周最高：36.25

52周最低：19.26

股本：6,646.04萬

流通股本：5,441.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.3106

淨資產收益率：--

總資產收益率：--

市淨率：9.77

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

全球最高價藥物再次易主，天價基因療法值不值？

21世纪经济报道

全球最貴藥物再次刷新！藍鳥生物基因療法獲FDA批准，價格出爐

藍鳥生物公司(BLUE)盤前漲近20% 旗下SKYSONA獲FDA加速批准用於治療早期活性CALD

凤凰网港股

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CALD"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CALD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CALD\",,,,,undefined,":{"symbol":"CALD","market":"US","secType":"STK","nameCN":"卡利都斯軟件","latestPrice":36,"timestamp":1523995200000,"preClose":36,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":54410000,"shares":66460419,"eps":-0.310592,"marketStatus":"停牌","change":0,"latestTime":"02-10 08:54:05 EST","open":36,"high":36,"low":36,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.310592,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1770733800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1069304400000,"exchange":"NASDAQ","adjPreClose":36,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CALD\",,,,,undefined,":{"symbol":"CALD","floatShares":54410000,"roa":"--","roe":"--","lyrEps":0,"shares":66460419,"dividePrice":0,"high":36,"amplitude":0,"preClose":36,"low":36,"week52Low":19.255,"pbRate":"9.77","week52High":36.25,"institutionHeld":1.004,"latestPrice":36,"eps":-0.310592,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.310592,"open":36,"prevYearClose":36},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CALD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-02-08","symbol":"CALD","fiscalQuarterEnding":"2017/12","expectedEps":0.11,"name":null,"time":"盤後","type":"earning","dateTimestamp":1518066000000,"reportTimeType":"post","actualEps":0.09},{"market":"US","date":"2017-11-02","symbol":"CALD","fiscalQuarterEnding":"2017/09","expectedEps":-0.05,"name":null,"time":"盤後","type":"earning","dateTimestamp":1509595200000,"reportTimeType":"post","actualEps":-0.02},{"market":"US","date":"2017-08-03","symbol":"CALD","fiscalQuarterEnding":"2017/06","expectedEps":-0.07,"name":null,"time":"盤後","type":"earning","dateTimestamp":1501732800000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2017-05-04","symbol":"CALD","fiscalQuarterEnding":"2017/03","expectedEps":-0.07,"name":null,"time":"盤後","type":"earning","dateTimestamp":1493870400000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2017-02-07","symbol":"CALD","fiscalQuarterEnding":"2016/12","expectedEps":-0.04,"name":null,"time":"盤後","type":"earning","dateTimestamp":1486443600000,"reportTimeType":"post","actualEps":-0.06}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CALD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CALD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CALD\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2286132187","title":"全球最高價藥物再次易主，天價基因療法值不值？","url":"https://stock-news.laohu8.com/highlight/detail?id=2286132187","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2286132187?lang=zh_tw&edition=fundamental","pubTime":"2022-11-26 17:33","pubTimestamp":1669455180,"startTime":"0","endTime":"0","summary":"基因疗法可引入功能基因来替代突变基因，以纠正或补偿缺陷和异常基因引起的疾病。　　21世纪经济报道记者 魏笑 深圳报道 11月22日，美国FDA宣布澳大利亚制药公司CSL Behring的治疗B型血友病的一次性基因疗法Hemgenix获批，定价为350万美元，刷新了世界上最昂贵治疗方法的记录。　　在不到半年的时间里，“全球最贵药物”已三易其主。　　值得注意的是，这几款药物均为基因治疗产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/world/gjcj/2022-11-26/doc-imqmmthc6096666.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/gjcj/2022-11-26/doc-imqmmthc6096666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AAV","CALD"],"gpt_icon":0},{"id":"2269718295","title":"全球最貴藥物再次刷新！藍鳥生物基因療法獲FDA批准，價格出爐","url":"https://stock-news.laohu8.com/highlight/detail?id=2269718295","media":"药融云","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2269718295?lang=zh_tw&edition=fundamental","pubTime":"2022-09-20 14:49","pubTimestamp":1663656598,"startTime":"0","endTime":"0","summary":"据药融云数据显示，蓝鸟生物该基因疗法最早于2021年7月16日首次全球面世，上市国家包括欧盟、挪威、冰岛等国家，获批适应症为肾上腺脑白质营养不良。蓝鸟生物目前拥有约300名员工，比1月底减少了42%。蓝鸟生物预计其现金和短期收入将在2024年上半年为公司带来收益。目前该公司对镰状细胞疾病的基因治疗处于临床研究阶段，没有得到美国FDA的批准，安全性和疗效尚未确定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_3932040000_ea5e2b40001010t8x.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_3932040000_ea5e2b40001010t8x.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["CALD"],"gpt_icon":0},{"id":"2268996322","title":"藍鳥生物公司(BLUE)盤前漲近20% 旗下SKYSONA獲FDA加速批准用於治療早期活性CALD","url":"https://stock-news.laohu8.com/highlight/detail?id=2268996322","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2268996322?lang=zh_tw&edition=fundamental","pubTime":"2022-09-19 16:27","pubTimestamp":1663576058,"startTime":"0","endTime":"0","summary":"蓝鸟生物公司盘前涨近20%，报7.56美元。蓝鸟生物宣布，美国食品和药物管理局已批准SKYSONA，也被称为elicel，用于减缓4-17岁早期活跃性脑肾上腺脑白质营养不良男孩神经功能障碍的进展。作为SKYSONA加速批准的条件之一，蓝鸟同意向FDA提供确认性的长期临床数据。蓝鸟将美国SKYSONA的批发收购成本定为300万美元。SKYSONA生物制剂许可证申请被美国FDA优先审查，蓝鸟在批准后获得了罕见的儿科优先审查凭证。SKYSONA此前被授予孤儿药、罕见儿科疾病和突破性治疗称号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=e4472459a5bedd3ce65e0d6c75962e4f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CALD","BK4139","BK4578","BLUE","BK4556"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CALD\",params:#limit:6,delay:false,,,undefined,":[]}}